Adalimumab (HUMIRA®) monotherapy provides sustained long-term improvement in health utility in patients with rheumatoid arthritis (RA)

被引：0
|
作者：
Dietz, BM
Van de Putte, LBA
Holtbrügge, W
Kupper, H
Raschke, U
Unnebrink, K
Sterz, R
机构：
[1] Abbott GmbH & Co KG, Hlth Econ & Outcomes Res, Ludwigshafen, Germany
[2] Univ Nijmegen, Dept Rheumatol, Nijmegen, Netherlands
[3] Stat & Datenverarbeitung GmbH, STATIS, Mannheim, Germany
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2005年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：393 / 393
页数：1
相关论文
共 50 条
  • [1] Adalimumab (HUMIRA®) monotherapy significantly improves health utility in patients with severe rheumatoid arthritis (RA)
    Dietz, BM
    Sterz, R
    Holtbrügge, W
    Kupper, H
    Van de Putte, LBA
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 392 - 392
  • [2] The cost-utility of adalimumab (Humira) in patients with rheumatoid arthritis (RA) in Denmark
    Aagren, M.
    Davies, A.
    Pang, F.
    Winding, B.
    [J]. VALUE IN HEALTH, 2006, 9 (06) : A223 - A223
  • [3] Adalimumab (HUMIRA®) monotherapy significantly improves fatigue in patients with severe rheumatoid arthritis (RA)
    Dietz, BM
    Sterz, R
    Holtbrügge, W
    Kupper, H
    Van de Putte, LBA
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 392 - +
  • [4] Sustained efficacy of adalimumab (HUMIRA™) plus methotrexate in rheumatoid arthritis (RA) patients.
    Schiff, MH
    Weisman, MH
    Furst, DE
    Kavanaugh, A
    Fischkoff, SA
    Spencer-Green, GT
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S314 - S315
  • [5] Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (HUMIRA®)
    Anis, AH
    Guh, D
    Melilli, LE
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A27 - A27
  • [6] SUSTAINED EFFICACY OF ADALIMUMAB (HUMIRA®) PLUS METHOTREXATE (MTX) IN RHEUMATOID ARTHRITIS (RA) PATIENTS
    Schiff, M. H.
    Weisman, M.
    Furst, D. E.
    Kavanaugh, A.
    Spencer-Green, G.
    Segurado, O. G.
    [J]. RHEUMATOLOGY, 2004, 43 : 40 - 40
  • [7] Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (HUMIRA®)
    Guh, D
    Bansback, NJ
    Nosyk, B
    Melilli, LE
    Anis, A
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 401 - 401
  • [8] Effects of adalimumab monotherapy on health utility and fatigue in patients with long-standing, severe rheumatoid arthritis (RA)
    Mittendorf, T
    Sterz, R
    Greiner, W
    Von der Schulenburg, J
    Cifaldi, M
    Dietz, B
    [J]. VALUE IN HEALTH, 2005, 8 (03) : 342 - 342
  • [9] Sustained 5-year efficacy of adalimumab (HUMIRA™) monotherapy in DMARD-refractory rheumatoid arthritis (RA).
    van de Putte, LBA
    Rau, R
    Burmester, GR
    Hartz, D
    Fischkoff, SA
    Kupper, H
    Spencer-Green, GT
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S314 - S314
  • [10] Sustained radiographic inhibition with adalimumab (HUMIRA™) over 2 years in patients with long standing rheumatoid arthritis (RA).
    Keystone, EC
    Kavanaugh, A
    Sharp, JT
    Spencer-Green, GT
    Fischkoff, SA
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S315 - S315
12345